Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
暂无分享,去创建一个
Gordon B Mills | Ken Chen | Peter Buchwald | Bin Wang | Christopher P Crum | G. Mills | K. S. Hale | Wenbin Liu | Ken Chen | J. Brugge | J. Harrell | T. Ince | C. Crum | B. Rueda | P. Buchwald | L. Selfors | Sizhen Gao | M. Krohn | A. Agoston | G. Mills | R. Foster | M. Merritt | Tan A Ince | Zhanna Kozhekbaeva | Joan S Brugge | Agoston T Agoston | Bo R Rueda | Michelle A. Jones | Wenbin Liu | Melissa A Merritt | P. Sergent | Katherine S Hale | J Chuck Harrell | Aurea D Sousa | Michelle A Jones | Elin S Agoston | Marit Krohn | Laura M Selfors | Mao Yong | Evan Cohick | Petra Sergent | Abigail Witt | Zhanna Kozhekbaeva | Sizhen Gao | Rosemary Foster | A. Witt | Petra A. Sergent | A. D. Sousa | E. Agoston | Bin Wang | Evan Cohick | M. Yong | K. Hale | Michelle Jones
[1] Craig E. Higgins,et al. Differential requirement for MEK/ERK and SMAD signaling in PAI-1 and CTGF expression in response to microtubule disruption. , 2009, Cellular signalling.
[2] W. McCluggage,et al. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.
[3] P. Menéndez,et al. The ROCK Inhibitor Y-27632 Negatively Affects the Expansion/Survival of Both Fresh and Cryopreserved Cord Blood-Derived CD34+ Hematopoietic Progenitor Cells , 2010, Stem Cell Reviews and Reports.
[4] G. Lowther,et al. Long-term culture of primary breast cancer in defined medium , 2005, Breast Cancer Research and Treatment.
[5] G. Mills,et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. , 2014, The Journal of clinical investigation.
[6] J. Bertoglio,et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing , 2001, Nature Cell Biology.
[7] Kakajan Komurov,et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.
[8] James D Iglehart,et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. , 2007, Cancer cell.
[9] M. Köbel,et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry , 2014, Histopathology.
[10] Susan Band Horwitz,et al. Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.
[11] J. Campisi. Cell biology: The beginning of the end , 2013, Nature.
[12] B. Têtu,et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. , 2006, International journal of oncology.
[13] Dennis C. Sgroi,et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis , 2003, Nature Cell Biology.
[14] D. Amadori,et al. Establishment and characterization of a new cell line from primary human breast carcinoma , 2004, Breast Cancer Research and Treatment.
[15] John Quackenbush,et al. Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes , 2013, PloS one.
[16] Hiroshi Iwasaki,et al. CD133+ Cancer Stem Cell–like Cells Derived from Uterine Carcinosarcoma (Malignant Mixed Müllerian Tumor) , 2011, Stem cells.
[17] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[18] R. Drapkin,et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.
[19] J. Boyd,et al. Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.
[20] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[21] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[22] S. Cook,et al. Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.
[23] Luis Chiriboga,et al. Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas , 2008, The American journal of surgical pathology.
[24] Kathleen R. Cho,et al. Ovarian cancer update: lessons from morphology, molecules, and mice. , 2009, Archives of pathology & laboratory medicine.
[25] C. Roberts,et al. ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.
[26] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[27] C. Huttenhower,et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. , 2014, Journal of the National Cancer Institute.
[28] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[29] J. Troge,et al. Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.
[30] American Type Culture Collection Standards Development Orga ASN-0002. Cell line misidentification: the beginning of the end , 2010, Nature Reviews Cancer.
[31] Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis , 2013, Clinical & Experimental Metastasis.
[32] Michael M Gottesman,et al. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.
[33] Alexander Kamb,et al. What's wrong with our cancer models? , 2005, Nature Reviews Drug Discovery.
[34] Kathleen R. Cho,et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.
[35] S. Leung,et al. Calculator for ovarian carcinoma subtype prediction , 2011, Modern Pathology.
[36] A. Whittemore,et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.
[37] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[38] K. Coombes,et al. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines , 2010, Breast Cancer Research and Treatment.
[39] S. Nishikawa,et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.
[40] A. Krasinskas,et al. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin. , 2011, American journal of clinical pathology.
[41] M. Olivé,et al. Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization , 1978, In Vitro.
[42] M. Westerfield,et al. Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.
[43] J. Ford. A beginning or an end? , 1987, Nature.
[44] S. Shah,et al. Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research , 2013, PloS one.
[45] S. Canevari,et al. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[46] Chris Albanese,et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.
[47] G. Pagès,et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function , 2003, Oncogene.
[48] B. Bryan,et al. Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. , 2010, Oncology reports.
[49] R. Bast,et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] H. Höfler,et al. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. , 1999, Cancer genetics and cytogenetics.
[51] Benjamin Frederick Ganzfried,et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. , 2014, Journal of the National Cancer Institute.
[52] A. Paradiso,et al. Preferential chemosensitization of PTEN‐mutated prostate cells by silencing the Akt kinase , 2007, The Prostate.
[53] D. Hancock,et al. Role of Bim in the survival pathway induced by Raf in epithelial cells , 2004, Oncogene.
[54] P. Yelick,et al. Cytogenetic instability of dental pulp stem cell lines , 2012, Journal of Molecular Histology.
[55] L. Seymour,et al. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] K. Cibulskis,et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.
[57] E Y LASFARGUES,et al. Cultivation of human breast carcinomas. , 1958, Journal of the National Cancer Institute.
[58] J. Aster,et al. Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts , 2012, Leukemia.
[59] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[60] Masters,et al. Cell line misidentification: the beginning of the end , 2010 .
[61] Stefan Heinrichs,et al. SNP array analysis in hematologic malignancies: avoiding false discoveries. , 2010, Blood.
[62] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[63] Kathleen R. Cho,et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.
[64] A. Salgado,et al. Failure of Y-27632 to improve the culture of adult human adipose-derived stem cells , 2015, Stem cells and cloning : advances and applications.
[65] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[66] S. Badve,et al. Phenotypic plasticity in normal breast derived epithelial cells , 2014, BMC Cell Biology.
[67] Ronald W. Davis,et al. Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.
[68] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[69] Hans Clevers,et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.
[70] K. Coombes,et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.
[71] C. Denkert,et al. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. , 2006, Anticancer research.
[72] Xuming He,et al. Non-parametric quantification of protein lysate arrays , 2007, Bioinform..